New Delhi, April 4 – Malaysia’s largest generic pharmaceutical manufacturer, CCM Duopharma Biotech Bhd (CCMD), a subsidiary of Chemical Company of Malaysia Bhd (CCM) has entered into a strategic alliance with India’s Natco Pharma Limited (Natco) and Biocon Limited (Biocon) to offer affordable cancer and insulin therapies in Malaysia.
The signing ceremonies, held yesterday, were witnessed by Malaysian Prime Minister, Datuk Seri Najib Tun Razak who was in India for a five-day official visit.
CCMD and Natco entered into a 15-year partnership via a Consultancy Service Agreement, Technology Transfer Agreement and Supply Agreement to build Malaysia’s first High Active Potent Ingredient Drug (HAPI) manufacturing facility to produce generic oncology medicines.
Through this strategic collaboration , Natco will provide facility design, manufacturing technology transfer as well as active pharmaceutical ingredients (API) to localize the manufacturing of eight cancer products in Malaysia over the next seven years.
The project has been proposed for the Entry Point Project (EPP) under the National Key Economic Areas (NKEA) by PEMANDU and will see CCMD allocate a total investment of RM 34.0 million.
The HAPI plant will see CCMD widen its product portfolio capabilities in offering generic oncology medicines to treat breast cancer, lung cancer, colorectal cancer, cervical cancer and blood cancer.
In a separate meeting, CCMD, through its subsidiary CCM Pharmaceuticals Sdn Bhd (CCMP) has formally received the appointment letter from Biocon as the authorised reseller for human insulins in Malaysia following the award of RM300 million contract under the Ministry of Health’s Off Take programme to supply human insulin to all government hospitals and clinics for a period of three years until Dec 1, 2019 to Biocon.